Our first product to serve these markets is the AURORA Tissue Imaging system.

The company is currently engaged in clinic training of the AURORAVision AI-Algorithm for use in TURBT, funded in part by a NIH/NCI grant. The company plans for FDA approval of AURORA by the end of 2024.

We are also engaged in a research study for algorithm development and training in radical prostatectomy surgery at AdventHealth, Orlando, Florida.